All In Biotech

Free tool

FAERS Monitor: Opdualag

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761234 or its brand name (Opdualag, Nivolumab, Relatlimab-Rmbw). Reports on generic versions are filed under their own applications.

Reports

515

Serious

342

66% of reports

Hospitalization

112

Death reported

107

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death76
  • off label use60
  • malignant neoplasm progression35
  • fatigue19
  • myocarditis19
  • product storage error19
  • product dose omission issue15
  • adverse event13
  • colitis13
  • rash13
  • diarrhoea12
  • myasthenia gravis12
  • acute kidney injury9
  • headache9
  • hypothyroidism9

Reports by year received

View as table
YearReports
20201
202246
2023111
2024106
2025134
2026117

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,644 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myocarditisSignal1967.843.61,183
myasthenia gravisSignal1260.834.7646
colitisSignal1314.08.2145
malignant neoplasm progressionSignal3514.010.1410
hypothyroidismSignal911.56.076
product storage errorSignal198.95.7125
adverse eventSignal135.83.447
deathSignal763.62.9146
off label useSignal602.82.270
acute kidney injurySignal92.41.36
product dose omission issueSignal152.11.38
rash131.20.70
fatigue191.00.60
diarrhoea120.80.41
headache90.60.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.